Physician profile
Danielle Haas
NPI 1861547564
$593.13
in general payments reported to CMS, 2019-2025
9 companies · $81.76 in 2025
The $81.76 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $13.83 · 2023: $143 · 2024: $355 · 2025: $81.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $559 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $559.30 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $414.02 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $47.56 | 2022-2025 | Wegovy |
| Pfizer INC. | $28.33 | 2023-2025 | |
| Ibsa Pharma INC. | $21.31 | 2024 | Tirosint, Licart |
| Csl Behring | $20.00 | 2024 | Kcentra |
| Axsome Therapeutics, INC. | $17.39 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $16.34 | 2023 | Rexulti |
| Merck Sharp & Dohme LLC | $14.61 | 2024 | Vaqta, Vaxneuvance, Vaxelis |
| Astrazeneca Pharmaceuticals LP | $13.57 | 2023 | Breztri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Haas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.